Roche’s Susvimo Gets FDA Approval for Diabetic Retinopathy
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg/mL intravitreal ocular...
Drug
Chongqing Genrix Bio’s GR2001 Tetanus Monoclonal Antibody NDA Accepted by NMPA
China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) recently announced that its New Drug...
Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation
German pharmaceutical giant Bayer (ETR: BAYN) this week initiated a Phase I clinical study for...
InnoCare Pharma’s Minjuvi Gains NMPA Approval for DLBCL Treatment
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the National Medical Products Administration (NMPA)...
Uni-Bio Science’s Generic Diquas Accepted for NMPA Review
China’s Uni-Bio Science Group (HKG: 0690) announced that a market filing for its generic version...
MicusRx’s Contezolid Sodium NDA Accepted for Review by NMPA
China-based Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) announced that a New Drug Application (NDA)...
Eli Lilly’s Kisunla Approved in Australia for Alzheimer’s Treatment
The Australian Therapeutic Goods Administration (TGA) this week approved Eli Lilly and Company’s (NYSE: LLY)...
Kexing Biopharm’s GB18 Receives FDA Approval for Tumor Cachexia Clinical Trial
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced receiving clinical trial approval from the US...
Accropeutics’ AC-201 Shows Positive Phase II Results in Psoriasis Treatment
Suzhou-based Accropeutics Bioscience announced positive results from a Phase II study for its AC-201 in...
Simcere’s FGFR2b-Targeting ADC SIM0686 Enters Phase I Clinical Study
China-based Simcere Pharmaceutical Group (HKG: 2096) announced the initiation of a Phase I clinical study...
Triastek’s T22 Gastric Retention Capsules Gain NMPA IND Clearance
Nanjing-based Triastek Inc., a pioneer in 3D-printed pharmaceutical formulations, has obtained Investigational New Drug (IND)...
Boehringer Ingelheim’s Metalyse Approved in China for Acute Ischemic Stroke
Germany-based pharmaceutical leader Boehringer Ingelheim announced receiving marketing approval from China’s National Medical Products Administration...
Kelun-Biotech’s Sacituzumab Tirumotecan Accepted for NMPA Review for HR+, HER2- Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that another indication approval filing for its...
Nuance Pharma’s Ohtuvayre Meets Primary Endpoints in COPD Study
China-based Nuance Pharma announced positive topline results from the ENHANCE-CHINA study (NCT05743075) for its nebulized...
AccurEdit Therapeutics’ ART001 Receives FDA RMAT Designation for ATTR
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Regenerative Medicine Advanced...
Antengene and MSD Collaborate on ATG-022 for Advanced Solid Tumors
China-based Antengene Corporation Limited (HKG: 6996) has entered into a collaboration with US major Merck,...
3SBio Registers Phase III Study for SSGJ-707 in Advanced NSCLC
China-based 3SBio Inc. (HKG: 1530) announced this week the registration of the first Phase III...
Ascletis Pharma Initiates ASC47-103 Study in US for Obesity Treatment
China-based Ascletis Pharma Inc. (HKG: 1672) announced the first subject dosing of the ASC47-103 study...
Abbisko’s Pimitinib Granted Priority Review for TGCT Treatment in China
Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its self-developed, highly selective small-molecule CSF-1R inhibitor,...
Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC
China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate...